AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20594555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 17030353 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy
Number of subjects: 218
Study 15944559 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (20 to 50 units)
Number of subjects: 30
Study 15944559 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 30
Study 12092010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens for gestational trophoblastic neoplasia
Number of subjects: 0
Study 12092010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized studies
Number of subjects: 0
Study 12092010 — intervention group
Group type: EXPERIMENTAL
Intervention: Management protocols
Number of subjects: 0
Study 12092010 — intervention group
Group type: EXPERIMENTAL
Intervention: Carefully planned prospective studies
Number of subjects: 0
Study 10342081 — intervention group
Group type: EXPERIMENTAL
Intervention: Moistened misoprostol
Number of subjects: 240
Study 10342081 — intervention group
Group type: COMPARATOR
Intervention: Dry misoprostol
Number of subjects: 240
Study 9110389 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological General Well‐being (PGWB) index
Number of subjects: 900
Study 9110389 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Symptom Rating Scale (GSRS)
Number of subjects: 900
Study 9110389 — intervention group
Group type: COMPARATOR
Intervention: Reference group (healthy controls)
Number of subjects: 900
Study 9110389 — intervention group
Group type: EXPERIMENTAL
Intervention: GORD patients
Number of subjects: 900
Study 1764652 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialist (CNS) interactions and care before and after hospital discharge
Number of subjects: 36
Study 6630968 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric CEA measurement in patients with gastric ulcer and gastric cancer
Number of subjects: 0
Study 6630968 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric CEA measurement
Number of subjects: 0
Study 30917017 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary medical male circumcision (VMMC)
Number of subjects: 0
Study 30917017 — intervention group
Group type: COMPARATOR
Intervention: Control group (uncircumcised men)
Number of subjects: 0
Study 28560658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 10 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 30 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 60 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 90 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradefovir 120 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: COMPARATOR
Intervention: Adefovir dipivoxil 10 mg
Number of subjects: 50
Study 28560658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25203281 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking inter-trial interval across different blocks of trials
Number of subjects: 0
Study 25203281 — intervention group
Group type: COMPARATOR
Intervention: Varying inter-trial interval from trial to trial
Number of subjects: 0
Study 26121880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobecutan® aerosol
Number of subjects: 0
Study 23026845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone with lithium or valproate
Number of subjects: 0
Study 23026845 — intervention group
Group type: COMPARATOR
Intervention: Placebo with lithium or valproate
Number of subjects: 0
Study 19744533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to pictures of fruits and vegetables (reading a picture book daily for two weeks)
Number of subjects: 20
Study 19744533 — intervention group
Group type: COMPARATOR
Intervention: No exposure (neophobic behavior towards unexposed foods)
Number of subjects: 20
Study 17550998 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone supplementation (100 mg im every 2 weeks for 26 weeks)
Number of subjects: 34
Study 17550998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 15047641 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg titrated to 100 mg)
Number of subjects: 252
Study 15047641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 11401641 — intervention group
Group type: COMPARATOR
Intervention: timolol
Number of subjects: 53
Study 11401641 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost (50 microg/ml once daily)
Number of subjects: 53
Study 11401641 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost in addition to timolol
Number of subjects: 53
Study 9400510 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief non-directive psychotherapy (1 to 12 sessions over 12 weeks)
Number of subjects: 136
Study 9400510 — intervention group
Group type: COMPARATOR
Intervention: Routine general-practitioner care
Number of subjects: 136
Study 8217970 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping the membranes
Number of subjects: 195
Study 8217970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sweeping)
Number of subjects: 195
Study 3736870 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin
Number of subjects: 0
Study 3736870 — intervention group
Group type: COMPARATOR
Intervention: Physostigmine
Number of subjects: 0
Study 30676213 — intervention group
Group type: EXPERIMENTAL
Intervention: Pole walking program (12 weeks)
Number of subjects: 123
Study 30676213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 29282768 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (3 g/day)
Number of subjects: 106
Study 29282768 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (max. 10 μg/h/7 days)
Number of subjects: 106
Study 29282768 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 106
Study 29282768 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal patches
Number of subjects: 106
Study 27572001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) for 24 months
Number of subjects: 1970
Study 27572001 — intervention group
Group type: COMPARATOR
Intervention: Short dual antiplatelet therapy (DAPT) for ≤6 months
Number of subjects: 1970
Study 24515307 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for contrast-induced nephropathy (CIN)
Number of subjects: 3945
Study 23398269 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicondition collaborative care intervention for chronic illnesses and depression
Number of subjects: 214
Study 23398269 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 214
Study 20940640 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic bands during squats
Number of subjects: 20
Study 20940640 — intervention group
Group type: COMPARATOR
Intervention: No elastic bands during squats
Number of subjects: 20
Study 18375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel 80 mg/m2
Number of subjects: 735
Study 18375893 — intervention group
Group type: COMPARATOR
Intervention: Every-3-weeks paclitaxel 175 mg/m2
Number of subjects: 735
Study 18375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab in HER-2 nonoverexpressors
Number of subjects: 735
Study 18375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel
Number of subjects: 735
Study 18375893 — intervention group
Group type: COMPARATOR
Intervention: Every-3-weeks paclitaxel
Number of subjects: 735
Study 16361020 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 16361020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard low‐intensity intervention
Number of subjects: 306
Study 16361020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard high‐intensity intervention
Number of subjects: 306
Study 16361020 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard swallowing therapy
Number of subjects: 306
Study 12873289 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 424
Study 12873289 — intervention group
Group type: COMPARATOR
Intervention: Soluble human insulin (HI)
Number of subjects: 424
Study 11077352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.2% solution (CIP)
Number of subjects: 232
Study 11077352 — intervention group
Group type: COMPARATOR
Intervention: Combination of polymyxin B, neomycin, and hydrocortisone suspension (PNH)
Number of subjects: 232
Study 8808861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg as needed, 12 to 24 hours before sexual activity)
Number of subjects: 22
Study 8808861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg as needed)
Number of subjects: 22
Study 8808861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 1442579 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg once daily
Number of subjects: 291
Study 1442579 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg once daily
Number of subjects: 291
Study 7031208 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily injections of mixed insulin
Number of subjects: 10
Study 7031208 — intervention group
Group type: COMPARATOR
Intervention: Single-dose insulin regimen
Number of subjects: 10
Study 7031208 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital evaluation
Number of subjects: 10
Study 7031208 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise
Number of subjects: 10
Study 7031208 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Peptide concentrations
Number of subjects: 10
Study 30795775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical combination containing Bifidobacterium longum BB536 and red yeast rice extract (10 mg/day monacolin K)
Number of subjects: 33
Study 30795775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29106031 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of valsartan/amlodipine (80/5 mg)
Number of subjects: 23
Study 25448024 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial laminectomy (n=34)
Number of subjects: 72
Study 25448024 — intervention group
Group type: COMPARATOR
Intervention: Lateral laminectomy (n=38)
Number of subjects: 72
Study 23414938 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg daily
Number of subjects: 62
Study 23414938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21989290 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with three doses of HepB (CHO) vaccine (20μg each) administered at zero, one, and six months.
Number of subjects: 448
Study 21989290 — intervention group
Group type: COMPARATOR
Intervention: Group I (anti-HBs < 0.1 mIU/mL)
Number of subjects: 448
Study 19329404 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest lifestyle intervention
Number of subjects: 79
Study 19329404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 79
Study 19329404 — intervention group
Group type: COMPARATOR
Intervention: Combined intervention group
Number of subjects: 79
Study 19329404 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 19329404 — intervention group
Group type: COMPARATOR
Intervention: Follow-up support
Number of subjects: 79
Study 17326736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson C circuit
Number of subjects: 20
Study 17326736 — intervention group
Group type: COMPARATOR
Intervention: Laerdal circuit
Number of subjects: 20
Study 16792344 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% edetic acid in sterile distilled water applied to the root surface for 2 minutes before grafting
Number of subjects: 10
Study 16792344 — intervention group
Group type: COMPARATOR
Intervention: Sterile distilled water (control)
Number of subjects: 10
Study 14737878 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (5 mg/mL, 30 microL applied topically)
Number of subjects: 16
Study 14737878 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 16
Study 10493207 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (50 mg on alternate days)
Number of subjects: 22071
Study 10493207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 7485814 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge generation
Number of subjects: 84
Study 7485814 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug (Placebo) Consumption
Number of subjects: 84
Study 7485814 — intervention group
Group type: COMPARATOR
Intervention: Water control
Number of subjects: 84
Study 1791769 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly (17 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Number of subjects: 51
Study 1791769 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly (34 patients) vaginal administration of 25 micrograms 17 beta-oestradiol (E2)
Number of subjects: 51
Study 1791769 — intervention group
Group type: EXPERIMENTAL
Intervention: Two years of twice-weekly treatment (9 women)
Number of subjects: 51
Study 7199806 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 812
Study 7199806 — intervention group
Group type: COMPARATOR
Intervention: Not using oral contraceptives (Control)
Number of subjects: 812
Study 30043065 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (5, 10, 15, or 20 mg/d)
Number of subjects: 300
Study 30043065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 30043065 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 300
Study 26731792 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (200 mg)
Number of subjects: 20
Study 26731792 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot (880 mg)
Number of subjects: 20
Study 26731792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg)
Number of subjects: 20
Study 26731792 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study 25750137 — intervention group
Group type: COMPARATOR
Intervention: No drainage (Group A)
Number of subjects: 96
Study 25750137 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage (Group B)
Number of subjects: 96
Study 23870427 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema Therapy (ST)
Number of subjects: 100
Study 23870427 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 100
Study 20889235 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% to 30% salicylic acid peels every 2 weeks for a total of 4 peels along with 4% hydroquinone cream to both sides of the face twice daily
Number of subjects: 20
Study 20889235 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream to both sides of the face twice daily
Number of subjects: 20
Study 18431244 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 57
Study 18431244 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus
Number of subjects: 57
Study 15987917 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a monotherapy
Number of subjects: 814
Study 15987917 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a plus lamivudine
Number of subjects: 814
Study 15987917 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 814
Study 12814993 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary phytoestrogen excretion
Number of subjects: 117
Study 12814993 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary isoflavonoids excretion
Number of subjects: 117
Study 12814993 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing excretion rate of mammalian lignans
Number of subjects: 117
Study 10585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone treatment (0.5 microg x kg(‐1) x min(‐1) for 24 hours)
Number of subjects: 24
Study 10585039 — intervention group
Group type: COMPARATOR
Intervention: Control (no milrinone treatment)
Number of subjects: 24
Study 10585039 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone treatment
Number of subjects: 24
Study 8708685 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (mean dose 133.2 units Dysport)
Number of subjects: 31
Study 8708685 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 31
Study 1708046 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg twice a day)
Number of subjects: 10
Study 1708046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (Bdp)
Number of subjects: 40
Study 6753091 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 30370831 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise (walking workstation for 2.5 hours a day, 5 days/week)
Number of subjects: 25
Study 30370831 — intervention group
Group type: COMPARATOR
Intervention: Control phase (normal work activity)
Number of subjects: 25
Study 28634432 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice bag application to femoral region
Number of subjects: 104
Study 28634432 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ice bag application)
Number of subjects: 104
Study 25890367 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive enhanced closure (AEC)
Number of subjects: 62
Study 25890367 — intervention group
Group type: COMPARATOR
Intervention: Conventional wire closure (CWC)
Number of subjects: 62
Study 25890367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 23711618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular IFNβ-1a (30 μg once a week)
Number of subjects: 38
Study 23711618 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IFNβ-1b (250 μg every other day)
Number of subjects: 38
Study 21825112 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric strengthening of the hamstring muscles using the Nordic hamstring exercise
Number of subjects: 942
Study 21825112 — intervention group
Group type: COMPARATOR
Intervention: Usual training program (control group)
Number of subjects: 942
Study 19285298 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) after surgery
Number of subjects: 126
Study 19285298 — intervention group
Group type: COMPARATOR
Intervention: Control group (liver resection combined with PVTT removal)
Number of subjects: 126
Study 17679585 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program
Number of subjects: 0
Study 15117710 — intervention group
Group type: EXPERIMENTAL
Intervention: Draw the Line/Respect the Line intervention
Number of subjects: 2829
Study 15117710 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2829
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent victimisation in year 8 (reported once or twice)
Number of subjects: 2680
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent victimisation for girls
Number of subjects: 2680
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent victimisation for boys
Number of subjects: 2680
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly reported victimisation in year 9
Number of subjects: 2680
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimisation prevalence in year 8
Number of subjects: 2680
Study 11532838 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms of anxiety or depression prevalence in year 8
Number of subjects: 2680
Study 9260115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivicaine with fentanyl
Number of subjects: 37
Study 9260115 — intervention group
Group type: COMPARATOR
Intervention: Bupivicaine alone
Number of subjects: 37
Study 8517562 — intervention group
Group type: EXPERIMENTAL
Intervention: Histoacryl Blue
Number of subjects: 81
Study 8517562 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 81
Study 2952478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole gel (0.75%)
Number of subjects: 59
Study 2952478 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 59
Study 31648374 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1 g
Number of subjects: 0
Study 31648374 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 0.5 g + ibuprofen 200 mg
Number of subjects: 0
Study 31648374 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol and ibuprofen (combined)
Number of subjects: 0
Study 30725064 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based intervention (GWBB), 5 weeks, 2 times per week
Number of subjects: 16
Study 30725064 — intervention group
Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 16
Study 27177997 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNB‐1b 500 µg
Number of subjects: 2244
Study 27177997 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNB‐1b 250 µg
Number of subjects: 2244
Study 27177997 — intervention group
Group type: EXPERIMENTAL
Intervention: GA 20 mg QD
Number of subjects: 2244
Study 23979360 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 30
Study 23979360 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (23 women and 10 men)
Number of subjects: 30
Study 23194185 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Obesity Prevention Series (POPS)
Number of subjects: 600
Study 23194185 — intervention group
Group type: EXPERIMENTAL
Intervention: Preschool Obesity Prevention Series (POPS) + Incredible Years Series (IYS)
Number of subjects: 600
Study 23194185 — intervention group
Group type: COMPARATOR
Intervention: Usual Head Start Exposure
Number of subjects: 600
Study 20724348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory illness interactive template (ARI‐IT)
Number of subjects: 12